Synaptogenix Inc (SNPX) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
Synaptogenix, Inc. is a biopharmaceutical company. The Company is principally focused on developing therapeutics for patients with neurodegenerative diseases and developmental disorders. The Company is focused on developing a product platform based on a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer's disease (AD). Bryostatin-1 is a Protein Kinase C Epsilon (PKC e), a and e activator that was originally developed as a potential anticancer drug. The Company is evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease.
Contact details
Important dates
General stock information
- Short code:
- SNPX
- ISIN:
- US87167T2015
- Market cap:
- $3.88 million
- Shares in issue:
- 20.39 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.